Fluzone High Dose (inactivated split virion; Sanofi Pasteur) Drug Overview & Product Profiles 2017-2026
DUBLIN, July 9, 2019 /PRNewswire/ -- The "Fluzone High-Dose" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Drug Overview
Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination. The high-dose vaccine is four times more concentrated than the standard Fluzone vaccine, hence providing a higher antibody response. Fluzone HD was approved for use in persons aged =65 years in the US in December 2009.
Analyst Outlook
The superior efficacy of Fluzone High-Dose (HD) (inactivated split virion trivalent influenza vaccine [TIV]; Sanofi Pasteur) compared to standard-dose inactivated influenza vaccines (IIVs) has positioned it as one of the preferred options for the elderly in the US.
Key Topics Covered:
OVERVIEW
Drug Overview
Product Profiles
Fluzone High-Dose : Seasonal influenza vaccines
LIST OF TABLES
Table 1: Fluzone High-Dose drug profile
Table 2: Approval history of Fluzone HD for seasonal influenza vaccination
Table 3: Late-phase trials of Fluzone HD for seasonal influenza vaccination
Table 4: Fluzone High-Dose for seasonal influenza - SWOT analysis
For more information about this report visit https://www.researchandmarkets.com/r/a9rp7r
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/fluzone-high-dose-inactivated-split-virion-sanofi-pasteur-drug-overview--product-profiles-2017-2026-300881681.html
SOURCE Research and Markets
